COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,003 Articles (22,627 medRxiv, 8,376 bioRxiv)

Most recent first Previous |  Page 1503: Articles 15021-15030  | Next

Potent neutralization of SARS-CoV-2 variants of concern by an antibody with a unique genetic signature and structural mode of spike recognition
Kramer, K. J., Johnson, N. V., Shiakolas, A. R., Suryadevara, N., Periasamy, S., Raju, N., Williams, J. K., Wrapp, D., Zost, S. J., Holt, C. M., Hsieh, C.-L., Sutton, R. E., Paulo, A., Davidson, E., Doranz, B. J., Crowe, J. E., Bukreyev, A., Carnahan, R. H., McLellan, J. S., Georgiev, I. S.
10.1101/2021.05.16.444004 — Posted: 2021-05-16
CovidExpress: an interactive portal for intuitive investigation on SARS-CoV-2 related transcriptomes
Djekidel, M. N., Rosikiewicz, W., Peng, J. C., Kanneganti, T.-D., Hui, Y., Jin, H., Hedges, D., Schreiner, P., Fan, Y., Wu, G., Xu, B.
10.1101/2021.05.14.444026 — Posted: 2021-05-16
Evaluation of SARS-CoV-2 rapid antigen diagnostic tests for saliva samples
Hagbom, M., Carmona-Vicente, N., Sharma, S., Olsson, H., Jamtberg, M., Nilsdotter-Augustinsson, A., Sjowall, J., Nordgren, J.
10.1101/2021.05.14.21257100 — Posted: 2021-05-16
Toxoplasmosis: An important risk factor for acquiring SARS-CoV-2 infection and a severe course of Covid-19 disease
Flegr, J.
10.1101/2021.05.15.21257257 — Posted: 2021-05-16 Discussion: Onsite
Hydroxychloroquine For Prophylaxis Of COVID-19 In Health Workers: A Randomized Clinical Trial.
Rojas-Serrano, J., Portillo-Vasquez, A. M., Thirion-Romero, I., Vazquez-Perez, J., Mejia-Nepomuceno, F., Ramirez-Venegas, A., Perez-Kawabe, K. M., Perez-Padilla, R., RESEARCH GROUP ON HYDROXYCHLOROQUINE FOR COVID-19
10.1101/2021.05.14.21257059 — Posted: 2021-05-16
Adherence and sustainability of interventions informing optimal control against COVID-19 pandemic
Di Domenico, L., Sabbatini, C. E., Boëlle, P.-Y., Poletto, C., Crepey, P., Paireau, J., Cauchemez, S., Beck, F., Noel, H., Levy-Bruhl, D., Colizza, V.
10.1101/2021.05.13.21257088 — Posted: 2021-05-16
A Predictive Modelling Framework for COVID-19 Transmission to Inform the Management of Mass Events
Donnat, C., Bunbury, F., Kreindler, J., Filippidis, F. T., El-Osta, A., Esko, T., Harris, M.
10.1101/2021.05.13.21256857 — Posted: 2021-05-16
Safety, immunogenicity and protection provided by unadjuvanted and adjuvanted formulations of recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in non-human primates
Pillet, S., Arunachalam, P. S., Andreani, G., Golden, N., Fontenot, J., Aye, P., Röltgen, K., Lehmick, G., Dube, C., Gobeil, P., Trepanier, S., Charland, N., D'Aoust, M.-A., Russell-Lodrigue, K., Blair, R. V., Boyd, S., Bohm, R. B., Rappaport, J., Villinger, F., Ward, B. J., Pulendran, B., Landry, N.
10.1101/2021.05.15.444262 — Posted: 2021-05-15
Fc-independent neutralization of SARS-CoV-2 by recombinant human monoclonal antibodies
Noy-Porat, T., Edri, A., Alcalay, R., Makdasi, E., Gur, D., Aftalion, M., Evgy, Y., Beth-Din, A., Levy, Y., Epstein, E., Radinsky, O., Zauberman, A., Lazar, S., Yitzhaki, S., Marcus, H., Porgador, A., Rosenfeld, R., Mazor, O.
10.1101/2021.05.15.443978 — Posted: 2021-05-15
Fatal breakthrough infection after anti-BCMA CAR-T therapy highlights suboptimal immune response to SARS-CoV-2 vaccination in myeloma patients
Aleman, A., Van Oekelen, O., Upadhyaya, B., Agte, S., Kappes, K., Beach, K., Srivastava, K., Gleason, C. R., PVI study group, , Wang, B., Mouhieddine, T. H., Tuballes, K., Geanon, D., Khan, Z., Gonzalez-Reiche, A. S., van Bakel, H., Mouskas, K., Simons, N. W., Charney, A. W., Kim-Schulze, S., Rahman, A., Sordillo, E. M., Krammer, F. M., Cordon-Cardo, C., Bhardwaj, N., Gnjatic, S., Merad, M., Brown, B. D., Sanchez, L., Chari, A., Jagannath, S., Simon, V., Wajnberg, A., Parekh, S.
10.1101/2021.05.15.21256814 — Posted: 2021-05-15

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).